Produção e avaliação comparativa de preços de produtos do Laboratório de Manipulação Farmacêutica - Ribeirão Preto – SP: experiência relacionada à Assistência Farmacêutica no SUS

Borella, Júlio Cézar; Pereira, Lúcia Helena Terenciani Rodrigues

doi:10.1590/1414-462x201700020272

Cited by 4 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another service connected to a compounding pharmacy of the health department, Borrella and Pereira (2017) showed that besides the large production capacity of a public pharmacy (34 thousand units in 2015), the unit cost of production for the state was between 186%-802% lower than the potential purchase from private pharmacies (Borella, Pereira, 2017).…”

Section: Discussionmentioning

confidence: 99%

Compounded drugs as an alternative to the therapeutical gaps of inborn errors of metabolism

Fachini

Malaquias

Nogueira

et al. 2023

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Inborn errors of metabolism are rare disorders with few therapeutic options for their treatments, which can make patients suffer with complications. Therefore, compounded drugs might be a promising option given that they have the ability of meeting the patient's specific needs, (i) identification of the main drugs described in the literature; (ii) proposal of compounding systems and (iii) calculation of the budgetary addition for the inclusion of these drugs into the Brazilian Unified Health System. The research conducted a literature review and used management data as well as data obtained from official Federal District government websites. The study identified 31 drugs for the treatment of inborn errors of metabolism. Fifty eight percent (58%) (18) of the medicines had their current demand identified, which are currently unmet by the local Health System. The estimated budget for the production of compounded drugs was of R$363,16.98 per year for approximately 300 patients. This estimated cost represents a budgetary addition of only 0.17% from the total of expenditures planned for drug acquirement. There is a therapeutic gap for inborn errors of metabolism and compounding pharmacies show potential in ensuring access to medicine therapy with a low-cost investment.

show abstract

Section: Discussionmentioning

confidence: 99%

Compounded drugs as an alternative to the therapeutical gaps of inborn errors of metabolism

Fachini

Malaquias

Nogueira

et al. 2023

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…Despite the lack of a public policy to encourage and to finance the production of manipulated medicines in SUS, the practice is already used in some health units through specific initiatives of states and municipalities, which acquire the medicines through public bidding or pharmaceutical production, the latter being a more common practice in hospital units [ 13 ]. Among the manipulation experiences in the public network, the one carried out in the city of Ribeirão Preto stands out, where the Pharmaceutical Manipulation Laboratory produces 46 presentations for SUS patients [ 39 ]. For the Tuberculosis Program, 3% sodium chloride was produced for inhalation, used as a stimulus for pulmonary secretions before collecting material for examination, for the Leprosy program, an ethyl ether:ethane mixture was produced, used to test the sensitivity of the skin on regions affected by the disease [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

“…Among the manipulation experiences in the public network, the one carried out in the city of Ribeirão Preto stands out, where the Pharmaceutical Manipulation Laboratory produces 46 presentations for SUS patients [ 39 ]. For the Tuberculosis Program, 3% sodium chloride was produced for inhalation, used as a stimulus for pulmonary secretions before collecting material for examination, for the Leprosy program, an ethyl ether:ethane mixture was produced, used to test the sensitivity of the skin on regions affected by the disease [ 39 ]. The vast majority of the presentations produced, however, are for topical use, such as 2% acetic acid solution and sunscreen [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

“…For the Tuberculosis Program, 3% sodium chloride was produced for inhalation, used as a stimulus for pulmonary secretions before collecting material for examination, for the Leprosy program, an ethyl ether:ethane mixture was produced, used to test the sensitivity of the skin on regions affected by the disease [ 39 ]. The vast majority of the presentations produced, however, are for topical use, such as 2% acetic acid solution and sunscreen [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Medicine manipulation: An alternative to mitigate therapeutic gaps in the Brazilian Unified Health System?

et al. 2022

View full text Add to dashboard Cite

Despite the various initiatives carried out in Brazil and in the world, the challenge of offering essential medicines in adequate presentations remains, especially to the public affected by diseases considered neglected and the pediatric population, for whom the therapeutic options remain limited. The main objective of this study was to evaluate the production of manipulated medicines as a strategy to mitigate therapeutic and access gaps to essential medicines within the Brazilian public health system, called the Unified Health System (SUS). The evaluation, carried out between 2020 and 2021, identified, among the medicines considered essential to the Brazilian health context, those unavailable, for which strategies were evaluated to mitigate the identified unavailability, which is conventionally called therapeutic gaps. For 57% (n = 235) of pharmaceutical presentations identified as therapeutic gaps in SUS, manipulation was identified as the best strategy to promote access. Of these presentations, 30% (n = 70) were identified as priorities in the context of patient care and were mainly related to the demands of the pediatric public and those affected by poverty-related diseases. Concerning poverty-related diseases, the absence of evidence on the development of a standard formula for drugs with indication for such diseases was demonstrated. The need for an annual investment of approximately US$74.75 per capita was estimated to offer treatments in adequate presentations to SUS users, which should reflect in the improvement of the quality of life of about 26 thousand people. It was observed that this investment amount corresponds to only 3% of the budget for the purchase of medicines financed exclusively by the Ministry of Health thorugh the Strategic Component of Pharmaceutical Assistance (CESAF) approved for 2021.

show abstract

“…No decorrer desse período, sempre houve intenção de adequação às novas legislações que entraram em vigor (RDC 67/2007, RDC 18/2013). Houve, também, por parte dessa unidade, o comprometimento em relação ao desenvolvimento de novas técnicas de produção e metodologias analíticas através do desenvolvimento de projetos de pesquisa em associação com a Universidade de Ribeirão Preto (UNAERP) e, eventualmente, com apoio financeiro da Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (13). Foi através dessas oportunidades de parcerias que houve condições para o desenvolvimento de ações relacionadas com o controle de qualidade dos insumos e produtos preparados.…”

Section: Introductionunclassified

Avaliação da produção de drogas vegetais, derivados vegetais e fitoterápicos do laboratório de manipulação farmacêutica para fornecimento ao Programa de Fitoterapia e Homeopatia da Secretaria Municipal da Saúde de Ribeirão Preto – SP

Borella

Teixeira

2018

VITTALLE, ISSN 1413-3563, Rio Grande, Brasil

Self Cite

View full text Add to dashboard Cite

O Programa de Fitoterapia e Homeopatia da Secretaria da Saúde de Ribeirão Preto foi um dos primeiros a atuar no estado de São Paulo, a partir de 1992. A demanda de produtos a base de plantas medicinais para este programa foi suprida pelo trabalho do Laboratório de Manipulação Farmacêutica. A partir dos dados relativos à produção deste setor, nos anos de atuação do programa (1994 até 2017), foi possível usar os resultados como parâmetro avaliativo da atuação deste programa no município de Ribeirão Preto - SP. Observou-se a existência de fases na atuação do programa, sendo a primeira (1994 a 2002) que se caracterizou pela diversidade de preparações (21 tipos) e um clínico com direito a prescrição. Nesta fase houve a produção de 4.318 unidades medicamentosas, com maior demanda para Calendula officinalis pomada 10% (737), Maytenus ilicifolia folhas (424), Passiflora alata tintura 20% (321) e Allium sativum cápsulas 500mg (314). Outra fase (2003 a 2015) teve como características a drástica diminuição da diversidade de preparações [2 tipos - Calendula officinalis pomada 10% (29.779) e Stryphnodendron adstringens creme a 10% (1.532)] e o aumento do número de unidades produzidas (31.311 unidades), pela possibilidade de indicação de uso ter sido ampliada para integrantes de equipes multiprofissionais da rede de saúde do município. Nos anos de 2016 e 2017, o Laboratório de Manipulação Farmacêutica passou por séria crise produtiva que estava associada à crise econômica e política, com consequente restrição na produção de itens para uso no programa.

show abstract

Produção e avaliação comparativa de preços de produtos do Laboratório de Manipulação Farmacêutica - Ribeirão Preto – SP: experiência relacionada à Assistência Farmacêutica no SUS

Cited by 4 publications

References 16 publications

Compounded drugs as an alternative to the therapeutical gaps of inborn errors of metabolism

Compounded drugs as an alternative to the therapeutical gaps of inborn errors of metabolism

Medicine manipulation: An alternative to mitigate therapeutic gaps in the Brazilian Unified Health System?

Avaliação da produção de drogas vegetais, derivados vegetais e fitoterápicos do laboratório de manipulação farmacêutica para fornecimento ao Programa de Fitoterapia e Homeopatia da Secretaria Municipal da Saúde de Ribeirão Preto – SP

Contact Info

Product

Resources

About